These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33469964)

  • 1. PMDA's Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory Challenge.
    Shimokawa M; Sato D; Wakao R; Arai H
    Clin Pharmacol Ther; 2021 Feb; 109(2):295-298. PubMed ID: 33469964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
    Maruyama H; Kondo T
    Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future development of artificial organs related with cutting edge emerging technology and their regulatory assessment: PMDA's perspective.
    Handa N; Mochizuki S; Fujiwara Y; Shimokawa M; Wakao R; Arai H
    J Artif Organs; 2020 Sep; 23(3):203-206. PubMed ID: 32112156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.
    Khan S; Carter M
    Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.
    Sato M; Ochiai Y; Kijima S; Nagai N; Ando Y; Shikano M; Nomura Y
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):413-415. PubMed ID: 28568566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
    Teixeira T; Kweder SL; Saint-Raymond A
    Clin Pharmacol Ther; 2020 Mar; 107(3):507-513. PubMed ID: 31449664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?
    Richardson E; Daniel G; Joy DR; Kweder SL; Maloney DM; Raggio MJ; Jarow JP
    Ther Innov Regul Sci; 2018 Nov; 52(6):793-798. PubMed ID: 29714587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the Internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning.
    Douw K; Vondeling H; Eskildsen D; Simpson S
    J Med Internet Res; 2003; 5(1):e6. PubMed ID: 12746211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan.
    Nakajima K; Chiba K; Tsubamoto H; Walsh J; Strawn L; Suwa T
    Invest New Drugs; 2013 Aug; 31(4):1051-5. PubMed ID: 23250712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Drug Development and Regulatory Science in China.
    Chen J; Zhao N
    Ther Innov Regul Sci; 2018 Nov; 52(6):739-750. PubMed ID: 29714583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Japanese regulations on companion diagnostics.
    Nagai S; Urata M; Sato H; Mikami M; Kuga W; Yanagihara R; Miyamoto D; Suzuki Y; Shikano M
    Nat Biotechnol; 2016 Feb; 34(2):141-4. PubMed ID: 26849515
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective.
    Kehoe T; Blind E; Janssen H
    Br J Clin Pharmacol; 2019 Jun; 85(6):1208-1212. PubMed ID: 30335197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
    Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
    Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H; Shibatsuji M; Yasuda N
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs.
    Neez E; Hwang TJ; Sahoo SA; Naci H
    Clin Pharmacol Ther; 2020 Mar; 107(3):541-552. PubMed ID: 31591708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory Frameworks in Times of Uncertainty.
    Breckenridge A
    Clin Pharmacol Ther; 2019 Mar; 105(3):553-554. PubMed ID: 30094808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MD reviewers' role in the new anticancer drug approval process in the newly established Japanese regulatory agency, PMDEC (Pharmaceuticals and Medical Devices Evaluation Center).
    Fujiwara Y
    Jpn J Clin Oncol; 1998 Nov; 28(11):653-6. PubMed ID: 9861230
    [No Abstract]   [Full Text] [Related]  

  • 19. Meeting Report: PMDA Public Workshop on Pharmacometrics at Japan.
    Kijima S; Ochiai Y; Ishiguro A
    CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):550-552. PubMed ID: 32914930
    [No Abstract]   [Full Text] [Related]  

  • 20. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
    Nagai S; Ozawa K
    Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.